Experienced in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Prapti A. Patel

Hematology Oncology | Transplant Surgery
2201 Inwood Rd, Nc8.106, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Philadelphia-Negative Chronic Myeloid Leukemia
2201 Inwood Rd, Nc8.106, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Prapti Patel is a Hematologist Oncology specialist and a Transplant Surgeon in Dallas, Texas. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

2201 Inwood Rd, Nc8.106, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: August 29, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Ruxolitinib, Venetoclax
Study Phase: Phase 1
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 1/Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug
Study Drugs: Liposomal Daunorubicin, Liposomal Cytarabine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Completed
Publish Date: March 25, 2025
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Intravenously Administered IO-202 and IO-202 + Azacitidine ± Venetoclax in Acute Myeloid Leukemia (AML) Patients With Monocytic Differentiation and in Chronic Myelomonocytic Leukemia (CMML) Patients
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Biological
Study Drug: IO-202
Study Phase: Phase 1
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia
Enrollment Status: Withdrawn
Publish Date: July 29, 2021
Intervention Type: Biological
Study Drug: Donor Stem Cell Transplantation
Study Phase: Phase 2
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 10 Less Clinical Trials

47 Total Publications

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML.
Journal: Blood advances
Published: March 12, 2025
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Robert H. Collins
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Robert H. Collins
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (0.1 miles away)
214-645-2700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Collins is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Collins is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Hsiao C. Li
Hematology Oncology | Hematology | Oncology
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Hsiao C. Li
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

5151 Maple Ave, 
Dallas, TX 
 (0.7 miles away)
214-266-3333
Languages Spoken:
English
See accepted insurances

Hsiao Li is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Li is rated as an Advanced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Waldenstrom Macroglobulinemia, Multiple Myeloma, and Bone Marrow Aspiration.

Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Yazan F. Madanat
Hematology Oncology | Hematology | Oncology
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Yazan F. Madanat
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (0.1 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Yazan Madanat is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Madanat is rated as an Elite provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 20 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile